These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Clinical trials in mitochondrial disorders, an update. Almannai M; El-Hattab AW; Ali M; Soler-Alfonso C; Scaglia F Mol Genet Metab; 2020; 131(1-2):1-13. PubMed ID: 33129691 [TBL] [Abstract][Full Text] [Related]
26. Mitophagy in neurodegeneration: an opportunity for therapy? Santos RX; Correia SC; Carvalho C; Cardoso S; Santos MS; Moreira PI Curr Drug Targets; 2011 Jun; 12(6):790-9. PubMed ID: 21269269 [TBL] [Abstract][Full Text] [Related]
27. Targetable Pathways for Alleviating Mitochondrial Dysfunction in Neurodegeneration of Metabolic and Non-Metabolic Diseases. Millichap LE; Damiani E; Tiano L; Hargreaves IP Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768878 [TBL] [Abstract][Full Text] [Related]
28. Turn up the power - pharmacological activation of mitochondrial biogenesis in mouse models. Komen JC; Thorburn DR Br J Pharmacol; 2014 Apr; 171(8):1818-36. PubMed ID: 24102298 [TBL] [Abstract][Full Text] [Related]
29. Mitochondrial diseases: Drosophila melanogaster as a model to evaluate potential therapeutics. Foriel S; Willems P; Smeitink J; Schenck A; Beyrath J Int J Biochem Cell Biol; 2015 Jun; 63():60-5. PubMed ID: 25666557 [TBL] [Abstract][Full Text] [Related]
30. New Therapeutics to Modulate Mitochondrial Function in Neurodegenerative Disorders. Wilkins HM; Morris JK Curr Pharm Des; 2017; 23(5):731-752. PubMed ID: 28034353 [TBL] [Abstract][Full Text] [Related]
31. Mitochondrial dysfunction in the development and progression of neurodegenerative diseases. Johnson J; Mercado-Ayon E; Mercado-Ayon Y; Dong YN; Halawani S; Ngaba L; Lynch DR Arch Biochem Biophys; 2021 May; 702():108698. PubMed ID: 33259796 [TBL] [Abstract][Full Text] [Related]
34. Maternally inherited mitochondrial respiratory disorders: from pathogenetic principles to therapeutic implications. Uittenbogaard M; Chiaramello A Mol Genet Metab; 2020; 131(1-2):38-52. PubMed ID: 32624334 [TBL] [Abstract][Full Text] [Related]
35. The mitochondria-targeted hydrogen sulfide donor AP39 improves health and mitochondrial function in a C. elegans primary mitochondrial disease model. Fox BC; Slade L; Torregrossa R; Pacitti D; Szabo C; Etheridge T; Whiteman M J Inherit Metab Dis; 2021 Mar; 44(2):367-375. PubMed ID: 33325042 [TBL] [Abstract][Full Text] [Related]
36. Mitochondrial therapeutic interventions in Alzheimer's disease. Van Giau V; An SSA; Hulme JP J Neurol Sci; 2018 Dec; 395():62-70. PubMed ID: 30292965 [TBL] [Abstract][Full Text] [Related]
37. Strategies for treating mitochondrial disorders: an update. Scarpelli M; Todeschini A; Rinaldi F; Rota S; Padovani A; Filosto M Mol Genet Metab; 2014 Dec; 113(4):253-60. PubMed ID: 25458518 [TBL] [Abstract][Full Text] [Related]
38. Mitochondrial enhancement for neurodegenerative movement disorders: a systematic review of trials involving creatine, coenzyme Q10, idebenone and mitoquinone. Liu J; Wang LN CNS Drugs; 2014 Jan; 28(1):63-8. PubMed ID: 24242074 [TBL] [Abstract][Full Text] [Related]
39. Signaling and Regulation of the Mitochondrial Unfolded Protein Response. Naresh NU; Haynes CM Cold Spring Harb Perspect Biol; 2019 Jun; 11(6):. PubMed ID: 30617048 [TBL] [Abstract][Full Text] [Related]
40. Creatine and its potential therapeutic value for targeting cellular energy impairment in neurodegenerative diseases. Adhihetty PJ; Beal MF Neuromolecular Med; 2008; 10(4):275-90. PubMed ID: 19005780 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]